Open AccessRecurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors
Author(s) -
Jiao Lyu,
Qi Zhang,
Chunli Chen,
Yu Xu,
Xunda Ji,
Jiakai Li,
Qiujing Huang,
Peiquan Zhao
Publication year - 2017
Publication title -
investigative ophthalmology and visual science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.935
H-Index - 218
eISSN - 1552-5783
pISSN - 0146-0404
DOI - 10.1167/iovs.16-20680
Subject(s) - medicine , retinopathy of prematurity , ranibizumab , hazard ratio , ophthalmology , proportional hazards model , retinal , survival analysis , fundus (uterus) , surgery , bevacizumab , gestational age , confidence interval , chemotherapy , pregnancy , genetics , biology
To investigate timing and risk factors of recurrent retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) monotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom